Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

This prospective randomized trial is designed to determine if a lower dose of
cyclophosphamide (1.5 gm/m2) will be as efficacious as the intermediate dose (3 gm/m2), based
on cell number collected, number of apheresis required and resource utilization.

Inclusion Criteria:

- All patients must have a pathologic diagnosis of one of the following malignancies:

Non-Hodgkin's Lymphoma, including B- and T-cell lymphoma Multiple Myeloma or another plasma
cell dyscrasia (Waldenstrom, Amyloidosis)

- The patient must be approved for transplant by the treating Transplant physician.

- This must be the patient's FIRST mobilization attempt.

- Patients are eligible if an autologous transplant is planned within approximately 12
months from the time of collection of cells.

- Prior Treatment: No previous cytotoxic chemotherapy within 4 weeks prior to initiation
of therapy. (This does not include immunomodulatory drugs (IMiDs), proteasome
inhibitors, monoclonal antibodies or steroids.)

- No radiation within 4 weeks of mobilization attempt.

- Age >18, and < 75 years

- No significant co-morbid medical or psychiatric illness that would significantly
compromise the patient's clinical care and chances of survival.

- Informed consent must be signed prior to the treatment. Patients must willingly
consent after being informed of the procedure to be followed, the nature of the
therapy, alternatives, potential benefits, side effects, risks and discomforts. (Human
protection committee approval of this protocol and a consent form is required.)

Exclusion Criteria:

- Medical, social, or psychological factors that would prevent the patient from
receiving or cooperating with the full course of therapy.

- Documented hypersensitivity to any of the drugs used in the protocol.